BioSpace News Archive

The global Bioinformatics market size is expected to be worth around USD 45.9 billion by 2030, according to a new report by Nova one advisor.

According to Nova one advisor, the global Collagen market size is expected to hit around USD 21.4 billion by 2030 from valued at USD 10.5 billion in 2021 and growing at a CAGR of 9.2% from 2022 to 2030.

Rady Children’s Institute for Genomic Medicine and PlumCare RWE, a Biotechnology and HealthCare data company, announced a partnership to establish the first international site for BeginNGS™, a pilot program to screen newborns for approximately 400 genetic diseases that have known treatment options using rapid Whole Genome Sequencing.

The global Endoscopic Retrograde Cholangiopancreatography market size was estimated at USD 1.9 billion in 2022 and is expected to surpass around USD 4.0 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 11.6% during the forecast period 2022 to 2030.

Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system diseases, announced the appointment of Ottavio V. Vitolo, M.D. as chief medical officer.

According to Nova one advisor, the global Regulatory Affairs Outsourcing market size is expected to hit around USD 13.85 billion by 2030 from valued at USD 6.20 billion in 2021 and growing at a CAGR of 8.40% from 2022 to 2030.

According to Nova one advisor, the global Soft Tissue Repair market was valued at USD 10.7 billion in 2022 and it is expected to hit around USD 21.2 billion by 2030 with a CAGR of 7.7% during the forecast period 2022 to 2030.

Isolation Bio, Inc., previously operating as General Automation Lab Technologies, Inc., has announced its rebranding effort to better reflect the company’s mission to provide innovative products and services that enable customers to do automated, fast and cost-effective isolation and cultivation of bacteria.

Kubota Vision Inc., a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd., announced positive results from a post hoc analysis of the phase 3 clinical trial of the investigational visual cycle modulator emixustat hydrochloride in patients with Stargardt Disease.

Edinburgh and Cambridge, UK, 03 October 2022 - Macomics Ltd, a biotech company with world-leading expertise in macrophage biology, congratulates its co-founder Prof. Jeffery Pollard Ph.D. on his election to the Academia Europaea (the European Academy, AE).